NYSE: GMEDGlobus Medical Inc Stock
$58.90-1.30 (-2.16%)
Updated Jun 13, 2025
GMED Price
$58.90
Fair Value Price
N/A
Market Cap
$7.97B
52 Week Low
$54.48
52 Week High
$94.93
P/E
43.31x
P/B
1.95x
P/S
3.99x
PEG
0.74x
Dividend Yield
N/A
Revenue
$2.51B
Earnings
$185.56M
Gross Margin
60.6%
Operating Margin
9.3%
Profit Margin
7.4%
Debt to Equity
0.15
Operating Cash Flow
$646M
Beta
0.96
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GMED Overview
Globus Medical, Inc. is a medical device company offering orthopedic (spine and trauma) implants and artificial joints. The company also makes the ExcelsiusGPS surgical robotic system for spine surgery. Globus Medical was founded in 2003 and is headquartered in Audubon, PA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GMED's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
GMED
Ranked#28 of 108
Ranked#28 of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $29.39 | A | |
| $12.10 | A | |
| $20.07 | A |
Be the first to know about important GMED news, forecast changes, insider trades & much more!
GMED News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GMED scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GMED ($58.90) is trading above its intrinsic value of $35.40, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GMED is poor value based on its earnings relative to its share price (43.31x), compared to the US market average (31.36x)
P/E vs Market Valuation
GMED is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more GMED due diligence checks available for Premium users.
Valuation
GMED price to earnings (PE)
For valuing profitable companies with steady earnings
Company
43.31x
Industry
35.6x
Market
31.36x
GMED is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GMED is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
GMED price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.95x
Industry
3.99x
GMED is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GMED price to earnings growth (PEG)
For valuing profitable companies with growth potential
GMED is good value based... subscribe to Premium to read more.
PEG Value Valuation
GMED's financial health
Profit margin
Revenue
$598.1M
Net Income
$75.5M
Profit Margin
12.6%
GMED's Earnings (EBIT) of $233.56M... subscribe to Premium to read more.
Interest Coverage Financials
GMED's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.7B
Liabilities
$623.1M
Debt to equity
0.15
GMED's short-term assets ($1.71B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GMED's short-term assets ($1.71B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GMED's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GMED's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$177.3M
Investing
$131.4M
Financing
-$635.4M
GMED's operating cash flow ($645.55M)... subscribe to Premium to read more.
Debt Coverage Financials
GMED vs Medical Device Stocks
Globus Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.